Fred Alger Management, LLC Biomarin Pharmaceutical Inc Transaction History

Fred Alger Management, LLC

$19.7 Billion
Q1 2024

A detailed history of Fred Alger Management, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Fred Alger Management, LLC holds 31,180 shares of BMRN stock, worth $2.56 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

31,180

Previous 33,389 6.62%

Holding current value

$2.56 Million

Previous $3.22 Million 15.41%

% of portfolio

0.01%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $185,136 - $218,691	-2,209 Reduced 6.62%	31,180 $2.72 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $571,116 - $738,135	-7,493 Reduced 18.33%	33,389 $3.22 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $571,245 - $634,433	-6,715 Reduced 14.11%	40,882 $3.62 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $7.4 Million - $8.56 Million	-85,326 Reduced 64.19%	47,597 $4.13 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $5.29 Million - $7.07 Million	60,297 Added 83.02%	132,923 $12.9 Million

Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $2.75 Million - $3.69 Million	33,940 Added 87.73%	72,626 $7.52 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $2.69 Million - $3.17 Million	-32,718 Reduced 45.82%	38,686 $3.28 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $3.67 Million - $4.46 Million	-51,391 Reduced 41.85%	71,404 $5.92 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $6.91 Million - $8.63 Million	-93,055 Reduced 43.11%	122,795 $9.47 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $12.6 Million - $16 Million	174,998 Added 428.37%	215,850 $19.1 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $201,953 - $230,854	2,701 Added 7.08%	40,852 $3.16 Million
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $582,257 - $653,815	7,711 Added 25.33%	38,151 $3.18 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $31.1 Million - $37.7 Million	-415,970 Reduced 93.18%	30,440 $2.3 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $4.83 Million - $6 Million	66,567 Added 17.52%	446,410 $39.1 Million
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $61.4 Million - $112 Million	-853,768 Reduced 69.21%	379,843 $28.9 Million
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $96.7 Million - $151 Million	1,215,604 Added 6750.73%	1,233,611 $152 Million
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $495,093 - $671,848	6,937 Added 62.66%	18,007 $1.52 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $277,260 - $372,600	4,314 Added 63.85%	11,070 $936,000
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $892,847 - $1.13 Million	-13,247 Reduced 66.23%	6,756 $455,000
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $285,483 - $333,626	3,553 Added 21.6%	20,003 $1.71 Million
Q1 2019 May 14, 2019	SELL	$84.2 - $98.62 $56.6 Million - $66.3 Million	-672,286 Reduced 97.61%	16,450 $1.46 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $13.2 Million - $17.5 Million	-164,677 Reduced 19.3%	688,736 $58.6 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $11.4 Million - $12.8 Million	-121,060 Reduced 12.42%	853,413 $82.8 Million
Q2 2018 Jul 19, 2018	BUY	$76.01 - $99.03 $3.03 Million - $3.95 Million	39,852 Added 4.26%	974,473 $91.8 Million
Q1 2018 May 10, 2018	SELL	$77.67 - $92.63 $6.94 Million - $8.28 Million	-89,411 Reduced 8.73%	934,621 $75.8 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $306,322 - $360,828	3,793 Added 0.37%	1,024,032 $91.3 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $82.2 Million - $96.9 Million	1,020,239	1,020,239 $95 Million

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.

Account

Fred Alger Management, LLC Biomarin Pharmaceutical Inc Transaction History